The Journal of Urology
Volume 173, Issue 2 , Pages 533-536 , February 2005

TESTOSTERONE REPLACEMENT THERAPY AFTER PRIMARY TREATMENT FOR PROSTATE CANCER

  • PIYUSH K. AGARWAL
    • ,
  • MICHAEL G. OEFELEIN

      Affiliations

    • Corresponding Author InformationCorrespondence: Western Reserve University School of Medicine, University Hospitals of Cleveland, 11100 Euclid Ave., Cleveland, Ohio 44106 (telephone: 216-844-3009; FAX: 216-844-1900).
    • Financial interest and/or other relationship with Novartis, Sanofi, Ferring and Atrix Laboratories.

References 

  1. Morales, A., Carson, C., Hellstrom, W., Lipshultz, L. and Morgentaler, A.: 2/11/2003 Position statement on Diagnosis, Treatment, and Monitoring of Male Late Onset Hypogonadism by Sexual Medicine Society of North America, Inc., A Specialty Society of the AUA. Available at http://www.smsna.org/about/dtmmloh.asp. Accessed July 2, 2004
  2. Harman SM , Metter EJ , Tobin JD , Pearson J , Blackman MR . Baltimore Longitudinal Study of Aging: Longitudinal effects of aging on serum total and free testosterone levels in healthy men . J Clin Endocrinol Metab . 2001;86:724
  3. Synder PJ , Peachey H , Berlin JA , Hannoush P , Haddad G , Dlewati A , et al.   Effects of testosterone replacement in hypogonadal men . J Clin Endocrinol Metab . 2000;85:2670
  4. Sih R , Morley JE , Kaiser FE , Perry HM , Patrick P , Ross C . Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial . J Clin Endocrinol Metab . 1997;82:1661
  5. Pope HG , Cohane GH , Kanayama G , Siegel AJ , Hudson JI . Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial . Am J Psychiatry . 2003;160:105
  6. Bhasin S , Buckwalter JG . Testosterone supplementation in older men: a rational idea whose time has not yet come . J Androl . 2001;22:718
  7. Bhasin S , Singh AB , Mac RP , Carter B , Lee MI , Cunningham GR . Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan . J Androl . 2003;24:299
  8. Gerstenbluth RE , Maniam PN , Corty EW , Seftel AD . Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement . J Androl . 2002;23:922
  9. Rhoden EL , Morgentaler A . Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia . J Urol . 2003;170:2348
  10. Carlson RH . Avoid testosterone in prostate cancer patients, experts advise . Urol Times . 2003;31:34
  11. Huggins CB , Stevens RB , Hodges CV . The effects of castration on advanced carcinoma of the prostate gland . Arch Surg . 1941;43:209
  12. Wei JT , Dunn RL , Litwin MS , Sandler HM , Sanda MG . Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer . Urology . 2000;56:899
  13. Rhoden EL , Morgentaler A . Risks of testosterone-replacement therapy and recommendations for monitoring . N Engl J Med . 2004;350:482
  14. Curran MJ , Bihrle W . Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate . Urology . 1999;53:423
  15. Loughlin KR , Richie JP . Prostate cancer after exogenous testosterone treatment for impotence . J Urol . 1997;157:1845
  16. Reiter RE , de Kernion JB . Epidemiology, etiology and prevention of prostate cancer . In: 8th ed..  Walsh PC ,  Retik AB ,  Vaughan ED ,  Wein AJ editor. Campbell’s Urology . vol. 4: Philadelphia: W. B. Saunders Co.; 2002;p. 3011; sect. XI, chapt. 85
  17. Van Weerden WM , Van Steenbrugge GJ , Van Kreuningen A , Moerings EPCM , De Jong FH , Schröder FH . Assessment of the critical level of androgen for growth response of transplantable human prostatic carcinoma (PC-82) in nude mice . J Urol . 1991;145:631
  18. Fowler JE , Whitmore EF . The response of metastatic adenocarcinoma of the prostate to exogenous testosterone . J Urol . 1981;126:373
  19. Morgentaler A , Bruning CO , DeWolf WC . Occult prostate cancer in men with low serum testosterone levels . JAMA . 1996;276:1904
  20. Hoffman MA , DeWolf WC , Morgentaler A . Is low serum free testosterone a marker for high grade prostate cancer? . J Urol . 2000;163:824
  21. Massengill JC , Sun L , Moul JW , Wu H , McLeod DG , Amling C , et al.   Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy . J Urol . 2003;169:1670
  22. Miller LR , Partin AW , Chan DW , Bruzek DJ , Dobs AS , Epstein JI , et al.   Influence of radical prostatectomy on serum hormone levels . J Urol . 1998;160:449
  23. Madersbacher S , Schatzl G , Bieglmayer C , Reiter WJ , Gassner C , Berger P , et al.   Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis . Urology . 2002;60:869

 Submitted for publication July 14, 2004.

PII: S0022-5347(05)60535-6

doi: 10.1097/01.ju.0000143942.55896.64

The Journal of Urology
Volume 173, Issue 2 , Pages 533-536 , February 2005

Article Tools

* Image Usage & Resolution